Scientists Target Epstein-Barr Virus with New Antibody

In the quiet persistence of viruses, some become so widespread that they blur into the background of human life. One such virus is the Epstein-Barr virus (EBV), a pathogen estimated to infect around 95% of people worldwide—often without noticeable symptoms, yet linked to serious long-term diseases.

Now, scientists have taken a significant step toward confronting it.

A Nearly Universal Virus EBV is part of the herpesvirus family and typically infects people early in life. Once inside the body, it remains there permanently, lying dormant but capable of reactivating later.

While many individuals never experience major effects, the virus has been associated with conditions such as:

Certain cancers Multiple sclerosis Chronic immune-related disorders This dual nature—common yet potentially dangerous—has made EBV a long-standing target for researchers.

The Antibody Breakthrough A research team from leading U.S. institutions has developed new monoclonal antibodies designed to block EBV from infecting human immune cells.

These antibodies work by targeting two key viral proteins:

gp350, which helps the virus attach to cells gp42, which enables it to enter and infect them By interfering with these mechanisms, the antibodies essentially prevent the virus from gaining a foothold.

In laboratory models using mice with human-like immune systems, one of these antibodies was able to completely prevent infection—a result researchers describe as a major advance.

Why This Is Difficult EBV has proven unusually challenging to target. Unlike many viruses, it can bind to almost all B cells, a central component of the immune system.

This ability allows it to hide and persist, making it difficult for both natural immunity and medical interventions to fully eliminate it.

To overcome this, scientists used genetically engineered mice capable of producing human-like antibodies, increasing the chances that these treatments could eventually work in people.

What It Could Mean If future trials confirm these findings, the implications could be wide-reaching:

Prevention: Protecting high-risk groups, such as transplant patients Treatment: Reducing the risk of EBV-related cancers and diseases Long-term control: Potentially stopping reactivation of the virus later in life It also opens the door to similar approaches for other persistent viruses.

The story of EBV is one of quiet ubiquity—an almost invisible presence shared by most of humanity. This new antibody does not erase that history, but it offers something different: the possibility of finally interrupting it. In that sense, the breakthrough is less about a single virus and more about a shift in approach—turning one of the most common infections on Earth from an accepted constant into something that might, one day, be controlled.

AI Image Disclaimer Illustrations are AI-generated and intended for conceptual representation only.

Source Check — Credible Media Presence Reuters · ScienceDaily · ScienceAlert · Nature · Medical Xpress